Algernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Biotech Investing
Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million Medical Device Investing
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis Biotech Investing
Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test Medical Device Investing
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12 Medical Device Investing
Bristol Myers Squibb Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia in Adult Patients with Moderate to Severe Ulcerative Colitis Biotech Investing
Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting Biotech Investing
Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific Advisory Board Biotech Investing
PENELOPE-B Trial of IBRANCE® in Early Breast Cancer Did Not Meet Primary Endpoint Pharmaceutical Investing
Final Results of National Institute of Allergy and Infectious Diseases' ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® for the Treatment of COVID-19 Biotech Investing
